Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-GNB: Antibiotics for MDR Gram-negative Infections
NCT07004049Phase 4Recruiting
- Sponsor
- National University of Singapore
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Inhalation Devices
- Countries
- 12
01
Overview
A Phase 4 trial of colistin, polymyxin B, sulbactam, tigecycline, eravacycline in bloodstream infection (BSI), ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), sponsored by National University of Singapore. Started Apr 2025; status: recruiting.
02
Drugs
colistinpolymyxin Bsulbactamtigecyclineeravacycline
03
Conditions
bloodstream infection (BSI)ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT07004049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004049.